Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$215→HK$164 | ― | 10.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$13.21 | ― | 44.40% | Reiterated | ||||
| JD.com, Inc. Class A | BUY HK$165→HK$155 | ― | -19.30% | Reiterated | J.P. Morgan Remains a Buy on JD.com, Inc. Class A (9618) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$160→HK$150 | ― | 5.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$165→HK$135 | ― | 5.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$661→HK$658 | ― | 9.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$166.8→HK$135.2 | ― | 9.40% | Reiterated | ||||
| Techtronic Industries | BUY HK$134→HK$121 | ― | 0.00% | Reiterated | Techtronic Industries (TTNDF) Gets a Buy from Macquarie | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$131→HK$110 | ― | 9.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$11.5→HK$12 | ― | 9.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$30→HK$35 | ― | 13.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$70→HK$90 | ― | 55.00% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$65 | ― | 30.60% | Reiterated | ||||
| Contemporary Amperex Technology Co., Limited Class H | BUY HK$343→HK$411 | ― | 13.10% | Reiterated | Goldman Sachs Reaffirms Their Buy Rating on Contemporary Amperex Technology Co., Limited Class H (3750) | |||
| China Resources Power Holdings Co | BUY HK$22→HK$23.2 | ― | -8.80% | Reiterated | HSBC Sticks to Their Buy Rating for China Resources Power Holdings Co (CRPJF) | |||
| China Longyuan Power Group | BUY HK$8.7→HK$9 | ― | -8.80% | Reiterated | HSBC Sticks to Their Buy Rating for China Longyuan Power Group (CLPXF) | |||
| Huaneng Power International | HOLD HK$5.2→HK$5.1 | ― | -8.80% | Downgraded | HSBC downgrades Huaneng Power International (HUNGF) to a Hold | |||
| Huadian Power International | HOLD HK$5 | ― | -8.80% | Downgraded | HSBC downgrades Huadian Power International (HPIFF) to a Hold | |||
| China Power International Development | BUY HK$3.5→HK$3.6 | ― | -8.80% | Reiterated | HSBC Sticks to Its Buy Rating for China Power International Development (CPWIF) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$79.29→HK$58.85 | ― | 6.30% | Reiterated | ||||
| CALB Co., Ltd. Class H | BUY HK$26 | ― | 21.80% | Initiated | CALB Co., Ltd. Class H (3931) Receives a New Rating from DBS | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$8.08→HK$6 | ― | 3.00% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$2.9→HK$3 | ― | 14.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$134 | ― | 5.70% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$360 | ― | 38.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$59.8→HK$75.3 | ― | 9.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$33.4 | ― | 12.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$28.75 | ― | 5.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$218 | ― | 11.00% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL HK$25→HK$18 | ― | 8.90% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$6.9→HK$10 | ― | 6.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$6.5→HK$6.75 | ― | 8.20% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$50.5→HK$51.5 | ― | 8.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$23→HK$24.5 | ― | 8.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$14.9→HK$17.1 | ― | 8.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL HK$2→HK$2.3 | ― | 8.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$13.6 | ― | 31.80% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$55.9→HK$108.4 | ― | 3.90% | Reiterated | ||||
| J&T Global Express Limited | BUY HK$8.1→HK$8.9 | ― | -8.50% | Reiterated | CLSA Keeps Their Buy Rating on J&T Global Express Limited (1519) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY HK$13.6 | ― | 31.80% | Initiated | ||||
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H | BUY HK$284.14→HK$406.74 | ― | -0.50% | Reiterated | Goldman Sachs Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) | |||
| Innovent Biologics | BUY HK$74.95→HK$96.22 | ― | -0.50% | Reiterated | Goldman Sachs Reaffirms Their Buy Rating on Innovent Biologics (IVBXF) | |||
| Everest Medicines Ltd. | HOLD HK$49.11→HK$64.27 | ― | -0.50% | Reiterated | Everest Medicines Ltd. (1952) Receives a Hold from Goldman Sachs | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD HK$34→HK$39 | ― | 4.00% | Reiterated | ||||
| Hansoh Pharmaceutical Group Company Limited | BUY HK$22.71→HK$34.83 | ― | -0.50% | Reiterated | Goldman Sachs Reaffirms Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692) | |||
| 3SBio | HOLD HK$9.37→HK$25.81 | ― | -0.50% | Reiterated | Goldman Sachs Sticks to Their Hold Rating for 3SBio (TRSBF) | |||
| InnoCare Pharma Ltd. | BUY HK$12.72→HK$18.41 | ― | -0.50% | Reiterated | Goldman Sachs Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969) | |||
| CARsgen Therapeutics Holdings Ltd. | SELL HK$10.01→HK$14.92 | ― | -0.50% | Reiterated | CARsgen Therapeutics Holdings Ltd. (2171) Receives a Sell from Goldman Sachs | |||
| China Medical System Holdings | BUY HK$12.57→HK$14.33 | ― | -0.50% | Reiterated | Goldman Sachs Sticks to Its Buy Rating for China Medical System Holdings (CHSYF) | |||
| CSPC Pharmaceutical Group | BUY HK$8.74→HK$9.62 | ― | -0.50% | Reiterated | Goldman Sachs Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF) |
Rows:
